Latus Bio, Inc.: Series AEngineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2Oct 4, 2026RoundOSLatus Bio, Inc.Company profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedAISeries A · AIBiotechUnited StatesHealthtechNorth AmericaSeries A